Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.

Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.

<h4>Background</h4>Intradermal priming with HIV-1 DNA plasmids followed by HIV-1MVA boosting induces strong and broad cellular and humoral immune responses. In our previous HIVIS-03 trial, we used 5 injections with 2 pools of HIV-DNA at separate sites for each priming immunization. The p...

Full description

Bibliographic Details
Main Authors: Patricia J Munseri, Arne Kroidl, Charlotta Nilsson, Agricola Joachim, Christof Geldmacher, Philipp Mann, Candida Moshiro, Said Aboud, Eligius Lyamuya, Leonard Maboko, Marco Missanga, Bahati Kaluwa, Sayoki Mfinanga, Lilly Podola, Asli Bauer, Karina Godoy-Ramirez, Mary Marovich, Bernard Moss, Michael Hoelscher, Frances Gotch, Wolfgang Stöhr, Richard Stout, Sheena McCormack, Britta Wahren, Fred Mhalu, Merlin L Robb, Gunnel Biberfeld, Eric Sandström, Muhammad Bakari
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0119629

Internet

https://doi.org/10.1371/journal.pone.0119629

Similar Items